ASTRIA THERAPEUTICS INC (ATXS)
US04635X1028 - Common Stock
Overall ATXS gets a fundamental rating of 3 out of 10. We evaluated ATXS against 574 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ATXS as it has an excellent financial health rating, but there are worries on the profitability. ATXS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ATXS had negative earnings in the past year.
ATXS had a negative operating cash flow in the past year.
In the past 5 years ATXS always reported negative net income.
ATXS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ATXS (-25.34%) is better than 74.30% of its industry peers.
ATXS has a better Return On Equity (-26.86%) than 81.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.34% | ||
| ROE | -26.86% | ||
| ROIC | N/A |
ROA(3y)-74.38%
ROA(5y)-72.91%
ROE(3y)-77.59%
ROE(5y)-79.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ATXS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATXS has more shares outstanding than it did 1 year ago.
ATXS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ATXS has an Altman-Z score of 17.58. This indicates that ATXS is financially healthy and has little risk of bankruptcy at the moment.
ATXS's Altman-Z score of 17.58 is amongst the best of the industry. ATXS outperforms 92.61% of its industry peers.
ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17.58 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ATXS has a Current Ratio of 21.87. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ATXS (21.87) is better than 94.89% of its industry peers.
A Quick Ratio of 21.87 indicates that ATXS has no problem at all paying its short term obligations.
ATXS's Quick ratio of 21.87 is amongst the best of the industry. ATXS outperforms 94.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 21.87 | ||
| Quick Ratio | 21.87 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.46% over the past year.
EPS 1Y (TTM)2.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ATXS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.82% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.37%
EPS Next 2Y10.47%
EPS Next 3Y6.82%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ATXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATXS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.47%
EPS Next 3Y6.82%
5. Dividend
5.1 Amount
No dividends for ATXS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASTRIA THERAPEUTICS INC
NASDAQ:ATXS (9/24/2024, 8:00:01 PM)
After market: 10.56 -1.94 (-15.52%)12.5
+0.27 (+2.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap705.38M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.34% | ||
| ROE | -26.86% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 21.87 | ||
| Quick Ratio | 21.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)2.46%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y28.37%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y